Can You Start Wegovy at 0.5 mg? The Dose Schedule Explained

The myth: 0.25 mg is just a placeholder you can skip

A question our prescribers hear most weeks is some version of: "Can I start on 0.5 mg Wegovy and get to the therapeutic dose faster?" The logic is understandable. If the 2.4 mg maintenance dose is where the meaningful weight loss happens, surely skipping the lower rungs saves time?

The evidence does not support that shortcut. The 0.25 mg opening dose is not a formality, it is designed to reduce the gastrointestinal side effects that make people abandon treatment in the first month. Nausea, vomiting, diarrhoea and stomach discomfort are all more likely to occur, and more likely to be severe, if the dose starts too high too quickly. The graduated schedule exists precisely because semaglutide changes how your gut moves and how quickly your stomach empties; your body needs time to adapt.

The NHS semaglutide medicines page reflects the licensed schedule clearly: 0.25 mg for four weeks, then 0.5 mg, then stepwise increases every four weeks under prescriber guidance. Starting at 0.5 mg is not part of that schedule.

So if you have been told by a seller that you can begin at 0.5 mg, that is worth questioning. A prescriber who follows the licensed pathway will almost always begin at 0.25 mg.

What the full titration ladder looks like from 0.5 mg onwards

Once the 0.25 mg phase is complete and tolerated, 0.5 mg is the natural next step, and it is where many people notice the first real changes in appetite. From there, the schedule typically continues: 1.0 mg, then 1.7 mg, then 2.4 mg, each held for around four weeks before moving up, provided the dose is tolerated and the prescriber is satisfied with progress.

With the MHRA's approval in January 2026 of a 7.2 mg dose (and a dedicated single-dose 7.2 mg pen approved on 14 April 2026 for adults with a BMI of 30 or above) the ladder now extends further than it did at launch. The full Wegovy dose schedule covers every step in detail, including what each phase is intended to achieve.

It is worth noting that reaching the maintenance dose takes several months, and not everyone titrates all the way to 2.4 mg or beyond. Your prescriber may pause titration at 1.0 mg or 1.7 mg if that dose suits you well. The decision about whether to increase is always a clinical one, made on review of your progress, side-effect profile and overall health. If you are curious about staying at 1 mg rather than titrating further, that is a conversation worth having at your next review.

Wegovy is a prescription-only medicine, none of these steps can be self-administered without a prescriber's input. For context on how Wegovy works as a treatment, our overview page covers the mechanism, eligibility and what to expect.

What to expect during the 0.25 mg and 0.5 mg phases

The first eight weeks of Wegovy treatment are where most people experience the steepest adjustment. Side effects during the 0.25 mg and 0.5 mg phases tend to be gastrointestinal: nausea is the most commonly reported, followed by loose stools, constipation, burping and indigestion. For most people these ease within days to a couple of weeks as the body adjusts.

Weight loss at these early doses is usually modest. That is expected. The 0.25 mg and 0.5 mg doses are tolerability phases; the clinical trial evidence (including the STEP 1 trial published in the New England Journal of Medicine, which reported around 15% average weight reduction over 68 weeks at the 2.4 mg maintenance dose) reflects outcomes at maintenance, not at the starter doses.

Practical things that help during this phase: eating smaller portions, avoiding very fatty or spicy food, staying well hydrated, and injecting on the same day each week. If side effects feel unmanageable, the right response is to contact your prescriber, not to increase or decrease the dose yourself.

If you are researching the step that comes after 0.5 mg, our page on moving to the 1 mg dose explains what that transition involves. And if you are weighing up whether Wegovy fits your situation at all, our free consultation connects you with a GPhC-registered prescriber who can review your history and answer that properly.

For a broader look at injectable and oral weight-loss treatments available in the UK, the weight-loss treatment overview is a useful starting point before you decide. If you are approaching the upper end of the titration ladder, our pages on moving to the 1.7 mg dose and what is involved in reaching 2.4 mg cover those steps in more detail.